drugset / Trial / NCT03527628
OPTmizing Advanced Stage HodgkIn LymphoMa patIentS Therapy
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is a prospective, multi-center, open-label, phase II clinical trial, aims to assess the effectiveness of the combination ACVD (Adriamycin, Cyclophosphamide, Vinblastine and Dacarbazine) and BV (Brentuximab Vedotin) in PET-2 positive advanced-stage HL patients, in order to improve the overall long-term disease control in the entire cohort of advanced-stage HL.
Timeline
- Start
- 2018-01-01
- Primary completion
- 2021-01-15
- Completion
- 2022-01-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Brentuximab Vedotin | Monoclonal antibody | 1.2 mg/kg | Intravenous |
| Background | Bleomycin | Unknown | 10000 unknown | — |
| Background | Cyclophosphamide | Other / unclassified | 400 mg/m2 | — |
| Background | Dacarbazine | Small molecule | 375 mg/m2 | — |
| Background | Doxorubicin | Other / unclassified | 25 mg/m2 | Other |
| Background | Vinblastine | Small molecule | 6 mg/m2 | Intravenous |